Bright Peak Therapeutics raises €96.3M Series B round
10 June 2021· Basel, Switzerland· health, biotechnology, protein_engineering, drug_discovery, b2b
To advance next-generation cytokine immunotherapies to treat cancer and autoimmune disease, develop their platform, and advance their Bright Peak Immunocytokines.
Investors
LeadRA Capital
Also participating
InvusVersant VenturesFidelity Management & Research CompanyQatar Investment AuthorityBlackRockAlexandria Venture Investmentsundisclosed leading healthcare investment fund
About Bright Peak Therapeutics
Stage
Series C
Headquarters
Basel, Switzerland
Founded
2017
Team Size
51–200
Sectors
healthbiotechnologyprotein_engineeringdrug_discoveryb2b